Home > Boards > US Listed > Biotechs > Opko Health Inc (OPK)

The sentiment about the stock has been dampened

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test PR Newswire (US) - 10/20/2020 8:00:00 AM
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020 GlobeNewswire Inc. - 10/13/2020 12:50:49 PM
OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools PR Newswire (US) - 10/9/2020 8:00:00 AM
Notice of Class Action Settlement Involving Purchasers of OPKO Health, Inc. Common Stock during the period of September 26, 2... PR Newswire (US) - 10/8/2020 9:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/15/2020 10:32:13 AM
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients GlobeNewswire Inc. - 9/15/2020 7:00:10 AM
TNS New Potential Home Run Report Available Now InvestorsHub NewsWire - 9/3/2020 8:35:00 AM
OPKO Health to Participate in Two September Investment Conferences GlobeNewswire Inc. - 9/2/2020 4:05:10 PM
OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program PR Newswire (US) - 9/2/2020 8:00:00 AM
OPKO Health's BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay PR Newswire (US) - 9/1/2020 3:55:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2020 8:41:29 AM
OPKO Health's GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services PR Newswire (US) - 8/12/2020 9:15:00 AM
OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio PR Newswire (US) - 8/6/2020 8:00:00 AM
OPKO Health to Participate in BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 8/5/2020 3:35:52 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2020 8:54:32 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 6:28:10 AM
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results GlobeNewswire Inc. - 7/30/2020 4:05:10 PM
OPKO Health to Report Second Quarter 2020 Financial Results on July 30, 2020 GlobeNewswire Inc. - 7/27/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/27/2020 7:58:39 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/24/2020 4:13:32 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/24/2020 4:10:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/23/2020 4:57:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/21/2020 6:08:20 AM
OPKO Health's BioReference Laboratories Awarded Commercial Surge Capacity Testing for COVID-19 Emergency Response Contract by... PR Newswire (US) - 7/20/2020 2:45:00 PM
Major League Soccer Chooses OPKO Health's BioReference Laboratories to Provide COVID-19 Testing for Players and Employees PR Newswire (US) - 7/9/2020 8:00:00 AM
investora2z   Thursday, 11/28/13 12:40:45 PM
Re: None
Post # of 13462 
The sentiment about the stock has been dampened after the news related to the short position by Lakewood. The position is worrying because earlier the company had a long position in the stock. Investors were perturbed by the change in stance. However, some analysts remain positive on the stock mainly based on the future potential of the company due to its pipeline and the numerous acquisition over the last few years. Another important factor is the support of Dr. Frost who has been instrumental in taking to stock to these high levels. He has been a buyer from the open market, and owns a significant percentage of the float. Short positions can backfire in case insiders like Dr. Frost decide to increase their position. On October 31, 20% of the float was short. This increases the possibility of a squeeze. An article on seekingalpha mentioned that the recent correction in the stock is an overreaction by the market to the Lakewood news. The stock may rebound, as it has already done, and move higher based on the potential of the company. The analyst also mentions that the high level of shorts could add to the buying pressure in case of a positive news. Dr. Frost has been active with his other companies as well, and recently Biozone Pharmaceuticals (BZNE) was merged with Cocrystal Discovery where Opko and Teva (TEVA) have a stake. For Opko, the valuations are mainly based on future prospects and the positivity associated with ownership by Dr. Frost. The investments may take time to materialize. Still, the recent performance of the stocks owned by Dr. Frost helps increase the probability of a strong rebound. However, it is good to be a bit cautious, and keep a watch on the volumes. The investors can either book partial profits or tag along with a stop loss.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences